A5006870353- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Lymphoma Diagnosis and Treatment
- Bone health and treatments
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Advanced Breast Cancer Therapies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Hematological disorders and diagnostics
- Bone Metabolism and Diseases
- Bone and Joint Diseases
- Cancer Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Pharmacological Effects and Toxicity Studies
- Folate and B Vitamins Research
- Cancer therapeutics and mechanisms
- Oral and gingival health research
- Antifungal resistance and susceptibility
- Ubiquitin and proteasome pathways
- Management of metastatic bone disease
Medical University Plovdiv
1996-2021
University Hospital Dr. Georgi Stranski
2002-2020
University Multipurpose Hospital for Active Treatment "Sveti Georgi"
2013-2017
National Institute of Emergency Medicine "Pirogov"
2012-2017
University Specialized Hospital for Active Treatment of Endocrinology
2009-2014
Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and has shown efficacy in phase 1 2 study
This randomized, open-label, parallel-group, multicenter study was designed to compare the efficacy and safety of bendamustine chlorambucil in previously untreated patients with advanced (Binet stage B or C) chronic lymphocytic leukemia (CLL).Patients (<or= 75 years age) were randomly assigned receive 100 mg/m(2)/d intravenously on days 1 2, 0.8 mg/kg (Broca's normal weight) orally 15; treatment cycles repeated every 4 weeks for a maximum six cycles. The response assessed according National...
We compared the safety and efficacy of siltuximab (S), an anti‐interleukin‐6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc) + B in patients relapsed/refractory multiple myeloma a randomized phase 2 study. Siltuximab was given by 6 mg/kg IV every weeks. On progression, discontinued high‐dose dexamethasone could be added to S/plc. Response progression‐free survival (PFS) were analyzed pre‐dexamethasone European Group for Blood Marrow Transplantation (EBMT) criteria. For...
Essentials High-quality data are lacking on use of prophylaxis in adults with hemophilia and arthropathy. SPINART was a 3-year randomized clinical trial late/tertiary vs on-demand therapy. Prophylaxis improved function, quality life, activity pain but not joint structure by MRI. improves function must start before bleeding onset to prevent arthropathy.Background Limited exist the impact severe A pre-existing disease. Objectives To describe bleeding, health structure, health-related...
Summary The efficacy of bendamustine versus chlorambucil in a phase III trial previously untreated patients with B inet stage B/C chronic lymphocytic leukaemia ( CLL ) was re‐evaluated after median observation time 54 months M ay 2010. Overall survival OS analysed for the first time. At follow‐up, investigator‐assessed complete response CR rate (21·0% vs 10·8%), progression‐free (21·2 8·8 months; P < 0·0001; hazard ratio 2·83) and to next treatment (31·7 10·1 0·0001) were improved over...
Here, we report the outcome of 226 myeloma patients presenting with extramedullary plasmacytoma or paraosseous involvement in a retrospective study conducted 19 centers from 11 countries. Extramedullary disease was detected at diagnosis relapse between January 2010 and November 2017. were observed 130 (92 38) 96 (84 12). The median time multiple to development 25.1 months (range 3.1-106.3 months) group (median follow up: 15 months). Imaging approach for computed tomography (n=133), positron...
A primary analysis of the ASPIRE study found that addition carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression-free survival (PFS) compared with alone (control in patients relapsed multiple myeloma (RMM). This post hoc examined outcomes from categorised by age. In group, 103/396 were ≥70 years old, control 115/396 old. Median PFS for <70 old was 28·6 months group versus 17·6 [hazard ratio (HR), 0·701]. 23·8 16·0 (HR, 0·753). For overall...
Background Thalidomide has potent antimyeloma activity, but no prospective, randomized controlled trial evaluated thalidomide monotherapy in patients with relapsed/refractory multiple myeloma.Design and Methods We conducted an international, randomized, open-label, four-arm, phase III to compare three different doses of (100, 200, or 400 mg/day) standard dexamethasone who had received one prior therapies. The primary end-point was time progression.Results In the intent-to-treat population...
Serum levels of OPG and RANKL their clinical correlations were analyzed in 66 newly–diagnosed patients with multiple myeloma (MM). RANKL/OPG ratios significantly increased advanced stages high grade bone disease (MBD), while showed a tendency to decrease. Renal failure modified the expression OPG. are informative markers for tumor burden MBD.
8509 Background: ENDEAVOR (NCT01568866) is comparing Kd with Vd in pts RMM. The primary endpoint progression-free survival (PFS). Secondary endpoints include overall (OS), response rate (ORR), of peripheral neuropathy (PN), and safety. Methods: Adults RMM 1-3 prior treatments were eligible; planned enrollment was 888 pts. Pts randomized 1:1 stratified by K or V (yes vs no), lines treatment (1 2-3), ISS stage intended route (IV SC). arm received (30-min IV infusion) on days (D) 1, 2, 8, 9,...
Background Imatinib 400 mg/day is the standard treatment for patients with chronic phase myeloid leukemia. Recent reports suggested higher and more rapid cytogenetic molecular responses doses of imatinib.Design Methods In this prospective international, multicenter III study, 227 pre-treated Philadelphia chromosome-positive, BCR-ABL-positive leukemia were randomized to a standard-dose imatinib arm (400 mg/day) or high-dose (800 6 months followed by as maintenance therapy). planned interim...
The majority of multiple myeloma (MM) patients are 65 years age or older at diagnosis [1]. However, treatment MM in the elderly remains challenging because typically have a hig...
TPS225 Background: CFZ, a next-generation selective, irreversible epoxyketone proteasome inhibitor, has promising single-agent activity in relapsed/refractory (R/R) MM and favorable side effect profile. CFZ is tolerable broad range of pts including those with baseline peripheral neuropathy (PN) or renal insufficiency. LEN/low-dose Dex (Rd) current standard care for relapsed MM. While the combination bortezomib + LEN moderate- to high-dose active R/R MM, it associated development PN majority...
8018^ Background: Preclinical studies of siltuximab (S), a chimeric anti-IL-6 mAb, in combination with bortezomib (B) indicate an additive to synergistic effect multiple myeloma (MM) cell lines. This randomized study evaluated the safety and efficacy S+B compared placebo (plc)+B pts relapsed/refractory MM after 1−3 prior tx lines, measurable disease but no B exposure. Methods: 286 were 1:1 S+B: B+plc. S 6 mg/kg or plc was given IV q2w. 1.3 mg/m 2 on d 1, 4, 8, 11, 22, 25, 29, 32 for max 4...
BACKGROUND Patients treated with intravenous immunoglobulins (IVIG) rarely experience symptomatic hemolysis. Although anti‐A and anti‐B isoagglutinins from the product are involved in most cases, actual mechanisms triggering hemolysis unclear. STUDY DESIGN AND METHODS A prospective, open‐label, multicenter, single‐arm clinical trial 57 patients immune thrombocytopenia IVIG (Privigen, CSL Behring) was conducted. RESULTS Twenty‐one received one infusion (1 g/kg) 36 two infusions (2 × 1 of...
Background Previous data suggest that the response of chronic myeloid leukemia cells to imatinib is dose-dependent. The potential benefit initial dose intensification in pre-treated patients with phase remains unknown.Design and Methods Two hundred twenty-seven were randomly assigned continuous treatment a standard (400 mg/day; n=113) or 6 months high-dose induction (800 mg/day) followed by as maintenance therapy (n=114).Results rates major complete cytogenetic responses significantly higher...